Treatment of Relapsed Acute Myeloid Leukemia

Abstract

This article is part of the Topical Collection on Leukemia Keywords Relapse AML I Salavage chemotherapy I Venetoclax I FLT3 inhibitors I IDH1/IDH2 inhibitors I CPX-351 Opinion statement Relapse is still a common scenario in acute myeloid leukemia (AML) treatment and occurs in 40-50% of younger and the great majority of elderly patients. The prognosis in relapsed AML patients is generally poor but depends largely on the timing of relapse (early versus late) and the possibility of allogeneic hematopoietic stem cell transplantation (HSCT). At the time of relapse, we again perform a mutational screening and cytogenetic analysis in all AML patients as clonal evolution of disease is frequent. Clinical trials should be first priority in all relapsed patients. In fit patients without prior transplant, we aim to perform HSCT after salvage therapy. In AML patients relapsing after HSCT and good performance status, intensive therapy can be considered with subsequent cellular therapy such as donor lymphocyte infusion (DLI) or a second HSCT. However, less than 20% of these patients are alive after 5 years. For those patients that are unfit, the therapeutic aim is to prolong life with acceptable quality of life. Here, hypomethylating agents (HMA), low-dose AraC (LDAC), and solely cytoreductive therapy with hydroxurea are options depending on first-line therapy. For those patients that have not been treated with venetoclax in first line, the combination therapy of venetoclax with demethylating agents achieves encouraging response rates. Venetoclax is currently also studied in combination with intensive salvage therapy. Importantly, for patients with isocitrate dehydrogenase (IDH) 1/2-mutated AML, ivosidenib, an IDH1 inhibitor, and enasidenib, an IDH2 inhibitor, present well-tolerated options in the setting of refractory or relapsed (r/r) disease even in elderly and heavily pretreated patients with response rates of 30-40%. Both substances have been approved by the U.S. Food and Drug Administration (FDA) for r/r AML patients with IDH1/2 mutations (but not yet by the European Medicines Agency (EMA)). For patients with FMS-like tyrosine kinase 3 (FLT3) mutations, treatment with the selective FLT3 inhibitor gilteritinib is well tolerated and leads to improved outcome compared with standard salvage therapy. The approval has been granted by the FDA and the EMA. Generally, we would recommend targeted therapy for IDH1/2-and FLT3-mutated AML if available. In order to improve outcome in relapsed AML, it

The role of ARHGAP9: clinical implication and potential function in acute myeloid leukemia

“…Acute myeloid leukemia (AML), which is caused by the malignant transformation of myeloid primordial cells, is the second most common type of leukemia diagnosed in adults and children. Despite the significant progress made in risk stratification, supportive care, multiagent chemotherapy intensification, and autologous or allogeneic hematopoietic stem cell transplantation (auto/allo-HSCT), the outcome for AML patients remains discouraging because of recurrence and refractory [ 1 , 2 ]. Approximately 10% to 40% of younger patients and a larger percentage of patients aged 60 and above have refractory after standard chemotherapy (40%–60%) [ 3 ].…”

“…chemotherapy intensification, and autologous or allogeneic hematopoietic stem cell transplantation (auto/ allo-HSCT), the outcome for AML patients remains discouraging because of recurrence and refractory [1,2]. Approximately 10% to 40% of younger patients and a larger percentage of patients aged 60 and above have refractory after standard chemotherapy (40%-60%) [3].…”

Iron Oxide Nanoparticles Combined with Cytosine Arabinoside Show Anti-Leukemia Stem Cell Effects on Acute Myeloid Leukemia by Regulating Reactive Oxygen Species

“…Acute myeloid leukemia (AML) accounts for approximately 30% of leukemia cases, it is the most frequently diagnosed type of acute leukemia in the elderly, and its drug-resistant relapse is common. 1 , 2 The disease is characterized by abnormal primitive medullary system cell proliferation, poor cell differentiation, and infiltration of bone marrow, peripheral blood, and other tissues such as liver, spleen, and lymph nodes. AML patients are also found to have common hematopoiesis suppression, white blood cell abnormality in qualitative nature and quantity, and decrease in erythrocytes and platelets.…”

Linalool inhibits the growth of human T cell acute lymphoblastic leukemia cells with involvement of the MAPK signaling pathway

“…Although, the use of combination chemotherapy regimens, including vincristine, daunorubicin, and prednisolone has gradually improved the clinical outcome of T-ALL over the last few decades, majority of patients with T-ALL eventually relapse (3,4). Allogenetic hematopoietic stem cell transplantation may be the only potential curative therapy (5) and is also essential to identify novel agents suitable for elderly and weak patients with T-ALL.…”